# Effect of Lactiplantibacillus Plantarum DAD-13 on Inflammatory Markers in ICU Sepsis Patients

> **NCT07072871** · NA · COMPLETED · sponsor: **PT Royal Medikalink Pharmalab** · enrollment: 30 (actual)

## Conditions studied

- Sepsis
- Systemic Inflammatory Response Syndrome (SIRS)
- Critical Illness

## Interventions

- **DIETARY_SUPPLEMENT:** Lactiplantibacillus plantarum DAD-13
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07072871
- **Lead sponsor:** PT Royal Medikalink Pharmalab
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-01
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07072871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07072871, "Effect of Lactiplantibacillus Plantarum DAD-13 on Inflammatory Markers in ICU Sepsis Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07072871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*